 NEW YORK, July 29, 2020 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS; Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, announced that it will report its financial results for the second quarter of 2020 together with a business update on Wednesday, August 5, 2020, after the close of the US market. The announcement will be followed by a conference call at 7:30 AM EDT 1:30 PM CET on Thursday, August 6, 2020, prior to the open of the US market. The live dial-in information for the conference call is:US Canada only: 1 877-407-3104 International: 1 201-493-6792In addition, a replay of the call will be available until August 20, 2020 by calling 1 877-660-6853 Toll Free US Canada; 1 201-612-7415 Toll Free International.Conference ID: 13688263 About CellectisCellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia AML, B-cell acute lymphoblastic leukemia B-ALL and multiple myeloma MM.Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market ticker: CLLS and on Euronext Growth ticker: ALCLS. For more information, visit Follow Cellectis on social media: cellectis, LinkedIn and YouTube.TALEN is a registered trademark owned by Cellectis.For further information, please contact:Media contacts: Jennifer Moore, VP of Communications, 917-580-1088, Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, contact: Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, available: 